Back grey_arrow_rt.gif
 
 
InterMune Sells Danoprevir Rights to Roche for $175 Million
 
 
  from Jules: this HCV protease IS the protease Roche is developing, with ritonavir boosting, its not a different protease, but Roche bought all the rights from Intermune who did the initial discovery of the drug.
 
-- Conference Call and Webcast Today at 4:30 p.m. EDT --
 
BRISBANE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash. In connection with this transaction, the collaboration agreement that InterMune and Roche entered into in October 2006 has been terminated. In addition, the companies are actively exploring ways to continue their ongoing work together on other HCV research programs. InterMune noted that as a result of this transaction, the company will make no further investment in danoprevir and that, including net proceeds from the transaction, it currently expects to have a cash balance of approximately $290 million at the end of 2010.
 
Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "After conducting a careful review of our strategy and financial position, we have decided to divest our rights to danoprevir to Roche. This transaction provides a very substantial non-dilutive cash infusion that allows us to continue to independently and aggressively pursue the registration and commercialization of pirfenidone in the US and EU, and eliminates our obligation to make significant ongoing investments related to the further development and commercialization of danoprevir. We are now in a very strong financial position that provides us with the resources and flexibility to maximize the value of pirfenidone, our largest and nearest-term value creation opportunity."
 
Conference Call and Webcast Details
 
InterMune will host a conference call today at 4:30 p.m. EDT to discuss the transaction. Interested investors and others may participate in the conference call by dialing 866-408-9480 (U.S.) or 706-643-9223 (international), conference ID# 16402032. A replay of the webcast and teleconference will be available approximately three hours after the call.
 
To access the webcast, please log on to the company's website at www.intermune.comat least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
 
The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 16402032. The webcast will remain available on the company's website until the company's next earnings call.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org